Bellerophon Therapeutics moves PAH treatment into phase II
- INOpulse, which was designed to be used for the treatment of pulmonary arterial hypertension (PAH), has completed enrollment for phase II trials.
- INOpulse is a portable device that delivers controlled pulses of nitric oxide as add-on therapy to other medications.
- Phase II studies, which involve 80 patients, should be completed by the end of the year.
Pulmonary arterial hypertension (PAH), extremely high hypertension in the pulmonary arteries, is life-limiting. According to US registry data for the period from 1998 to 2006, the five-year survival rate is 58%.
INOpulse is being developed for patients whose disease is progressing and need add-on treatment. The primary endpoint is a change in pulmonary vascular resistance at 16 weeks, while secondary endpoints include cardiac index, changes in the six-minute walk distance and changes in mean pulmonary arterial pressure.
- Pharmaceutical Business Review Bellerophon completes patient enrollment for Phase 2 Trial of INOpulse